PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients
- kenashman
- May 13
- 1 min read
Commentary | Video : UROToday 26 March 2025
Neeraj Agarwal speaks with Hannah McManus about research from the IRONMAN registry examining PSA responses and outcomes in metastatic hormone-sensitive prostate cancer patients.
Dr. McManus discusses findings from over 1,300 real-world patients across four countries receiving different treatment regimens. The study reveals that patients achieving undetectable PSA nadirs (<0.2) at six months have significantly lower relapse rates through 36 months, with the highest rates of undetectable PSA (>50%) observed in the ADT plus ARPI group. Importantly, about 10% of patients achieve undetectable status between 6-12 months, indicating treatment response can continue beyond early evaluation points. While survival data remains immature with only 18 months follow-up, both physicians discuss how these findings might inform clinical decisions regarding treatment breaks for patients experiencing side effects and potential intensification strategies for non-responders, highlighting ongoing trials addressing these questions.
